Name: Latest research reports of Divi's Laboratories Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Divi's Laboratories Ltd.
Rating: 3
Author: BOB Capital Markets Ltd.

Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer

6057.0000 30.50 (0.51%)

NSE Sep 15, 2025 15:31 PM

Volume: 152.4K

Divi's Laboratories Ltd.

23 May 2022

6057.00

0.51%

Divi's Labs (HOLD): Strong all-round beat but growth unsustainable cut to HOLD

Hold: Divi's Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Robust standalone Q4 revenue/EBITDA growth of 45%/57% YoY, ahead of consensus by 11%/17%

Number of FII/FPI investors increased from 922 to 990 in Jun 2025 qtr.